The FDA’s decision to block Moderna’s mRNA flu vaccine review, despite staff endorsements and clinical data showing over 80% efficacy,…
What FDA’s Moderna flu vaccine refusal means for biotech regulatory pathways
The FDA’s October 2023 refusal to review Moderna’s mRNA influenza vaccine over control group issues underscores regulatory hurdles for novel…